Balanced news tone
News Sentiment
KURA sentiment intelligence
Kura Oncology Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
56
Balanced news tone
59 relevant articles
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+3.2% over one week, +26.5% over four weeks, trend active, and near fair-value range.
Kura Oncology to Present First Long-Term Follow-Up Data
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
78/100 classification
One-week reaction
3.2%
Price confirming higher
Trend fit
Trend active
26.5% over four weeks
Fair value
-5.0%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
21
Neutral
31
Negative
7
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
TradingKey
Direct company coverage
Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis
Kura Oncology Inc (KURA) has a weak financial status and low operating efficiency, ranking 320 out of 388 in the Biotechnology & Medical Research industry with a financial score of 5.85. Despite this, its latest quarterly revenue increased by 29.47% year-over-year to $18.27 milli
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 01:40
- Source
- TradingKey
TradingKey
Direct company coverage
Kura Oncology Inc (KURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Kura Oncology Inc (KURA), focusing on its business segments and regional revenue contributions. However, it states that relevant financial data for FY2024, FY2025, and specific quarters have not yet been disclosed by the company. The
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 01:11
- Source
- TradingKey
MT Newswires
Direct company coverage
Kura Oncology, Kyowa Kirin Cancer Combo Therapy Extends Survival in AML Patients
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 12:55
- Source
- MT Newswires
GlobeNewswire
Direct company coverage
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 Jun 2026 12:02
- Source
- GlobeNewswire
Simply Wall St.
Direct company coverage
How The Kura Oncology (KURA) Investment Narrative Is Evolving Without New Analyst Revisions
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 06 Jun 2026 08:07
- Source
- Simply Wall St.
MT Newswires
Direct company coverage
Kura Oncology Plans Wider Platform Study for Darlifarnib Amid Recent Data on Anti-Tumor Activity
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 11:53
- Source
- MT Newswires
GlobeNewswire
Direct company coverage
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 10:53
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 12:32
- Source
- GlobeNewswire
Ad Hoc News
Direct company coverage
Kura Oncology stock (US50126D1028): FDA breakthrough nod and pipeline update draw investor focus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 May 2026 07:00
- Source
- Ad Hoc News
Market source
Direct company coverage
Some Analysts Just Cut Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 17 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Trimming Their Forecasts
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Analysts Have Lowered Expectations For Kura Oncology, Inc. (NASDAQ:KURA) After Its Latest Results
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Ad Hoc News
Direct company coverage
Kura Oncology stock (US50126D1028): Q1 earnings beat and analyst buys
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Ad Hoc News
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 30 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 20 Apr 2026 07:00
- Source
- Market source
Seeking Alpha
Direct company coverage
Kura Oncology: Poised For A Lift With Combinations (NASDAQ:KURA)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Apr 2026 07:00
- Source
- Seeking Alpha
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
simplywall.st
Direct company coverage
Need To Know: The Consensus Just Cut Its Kura Oncology, Inc. (NASDAQ:KURA) Estimates For 2026
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 06 Feb 2026 08:00
- Source
- simplywall.st
simplywall.st
Direct company coverage
Don't Ignore The Insider Selling In Kura Oncology
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jan 2026 08:00
- Source
- simplywall.st
Seeking Alpha
Direct company coverage
Kura Oncology: A Cautious Buy (NASDAQ:KURA)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 04 Dec 2025 08:00
- Source
- Seeking Alpha
Pharmaceutical Executive
Direct company coverage
Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML
- Tone
- Positive 66/100
- Event
- Regulatory and legal
- Published
- 14 Nov 2025 08:00
- Source
- Pharmaceutical Executive
Reuters
Direct company coverage
US FDA approves Kura-Kyowa's blood cancer therapy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Nov 2025 08:00
- Source
- Reuters
PR Newswire
Direct company coverage
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Nov 2024 08:00
- Source
- PR Newswire